Prevention of stroke is a major priority for patients with atrial fibrillation (AF), and there is robust clinical evidence demonstrating that oral anticoagulation (OAC) with vitamin K antagonists (eg, warfarin) can effectively prevent stroke or systemic embolism and reduce mortality in patients with AF. 1, 2 However, warfarin is associated with a significant increase in bleeding, including intracranial hemorrhage, and its other shortcomings related to adjusted dosing and myriad food and drug interactions are well known. Therefore, the emergence of non-vitamin K antagonist oral anticoagulants (NOACs) directly targeting thrombin or factor Xa was a welcome development for treatment of patients with AF. In each of their respective phase 3 trials, these agents were demonstrated to be at least as safe and as effective as warfarin, [3] [4] [5] [6] and as a group, they appear to hold significant advantages over warfarin. 7 However, the decision among anticoagulation strategies is primarily left to the physician, and guidelines have only recently expressed a preference for NAOCs, as a class, over warfarin. 8, 9 Physicians must first determine if a patient is eligible for a NOAC and then decide whether to institute NOAC or warfarin for stroke prevention. To date, little is known about how clinicians select patients to receive NOACs versus alternative therapy. The objectives of this analysis are (1) to describe current patterns of OAC use among patients initiating treatment for new-onset AF in community practice, (2) to describe patterns of selection for NOAC over warfarin, and (3) to describe factors associated with selection of a NOAC (vs warfarin).
Methods
Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF II) is a prospective, national registry of outpatients with AF. In contrast to the first phase, ORBIT-AF II was specifically geared toward assessing OAC treatment decisions, particularly in patients with new-onset AF. Therefore, the inclusion criteria specified that the patient either (a) be recently diagnosed with AF (within 6 months) and/or (b) be recently transitioned to a NOAC for stroke prevention (within 3 months). Additional inclusion criteria were adult patients 21 years or older with electrocardiographically confirmed AF not due to a reversible cause (eg, thyrotoxicosis, acute pulmonary embolism, post-cardiac surgery) who are followed clinically at least as frequently as every 6 months. Consecutive, eligible patients were enrolled from a nationally representative sample of primary care physicians, cardiologists, electrophysiologists, and neurologists.
Study coordination, site management, and data analyses were performed by the Duke Clinical Research Institute. Data entry was performed using a Web-based case report and derived primarily from the patient's medical record. Data elements included patient demographics, prior medical and surgical history, vital signs, electrocardiographic data, imaging and laboratory results, and medical and procedure therapies. Documentation of medical therapy included OAC therapies, as well as other medical therapies, such as antiplatelet, antiarrhythmic, and other cardiovascular medications. For anticoagulants, dosing was documented, as well as international normalized ratio data (for patients on warfarin) and any contraindications to OAC (as determined by the patient's physician). Additional details of the ORBIT-AF II design and rationale have been previously described. 10 The present analysis included only patients with newly diagnosed AF (defined as those with a new diagnosis of AF within the previous 6 months), who were initiated on OAC at baseline evaluation. We subsequently compared baseline characteristics among patients receiving each OAC therapy. Use of NOAC versus warfarin was also compared among subgroups of interest: by age, prior stroke, prior gastrointestinal bleeding, any prior major bleeding, CHA 2 DS 2 -VASc score (Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, Prior stroke, transient ischemic attack [TIA] , or thromboembolism,Vascular disease, Age 65-74 years, Sex category [female]), estimated glomerular filtration rate (eGFR), payer, provider specialty, and geographic region. Prior to multivariate comparisons, we also assessed site variability in use of each OAC agent. Lastly, factors associated with NOACs as class versus warfarin, and individual NOAC versus warfarin, were assessed using multivariable models.
Statistical methods
Univariate comparisons are presented as counts and percentages for categorical variables and medians (interquartile range) or means (standard deviation) for continuous variables. They were compared using the χ 2 test for categorical variables and the Wilcoxon rank sum test for continuous variables. χ 2 tests were also used to compare rates of NOAC use among subgroups of interest.
Site variability with respect to OAC use was measured using histograms with proportion of patients on the x-axis and proportion of sites on the y-axis for each agent. Sites with b10 subjects (n = 93 sites) were excluded from this and all subsequent aspects of these analyses.
Multivariable hierarchical logistic regression was used to identify factors significantly associated with selection of NOAC versus warfarin. Covariates included in the final model were determined using a backward selection process (see candidate covariates in the Supplemental Material, Supplementary Table 1), with an α for exclusion of .05. Logistic regression was used for this process, and then the final model was repeated using the hierarchical model to account for variation in OAC use by site. All sites were included in this analysis. Imputed data were used to account for any missing covariate data. All continuous variables were tested for linearity, and nonlinear relationships were accounted for using linear splines. The odds ratio (OR) of NOAC relative to warfarin use is presented for all covariates in the final hierarchical model, along with their corresponding 95% CI and P value. In addition, the median OR for site will be calculated. This measure quantifies the variation between sites and must be equal to 1 or greater. A value of 1 indicates that there is no variation between sites, whereas greater numbers indicate greater variation.
To identify factors associated with individual NOAC selection, multivariable hierarchical logistic regression Values are presented as percentage or median (interquartile range), unless noted otherwise. ⁎ As calculated by the Cockcroft-Gault formula.
13 models were used. Covariate candidates and selection are similar to above. Logistic regression was used for this process, and then the final model was repeated using the hierarchical model to account for variation in NOAC/ warfarin use by site. Because of a significant number of sites that used either exclusively 1 OAC or warfarin and 1 specific NOAC, a single model with all NOACs could not be created (because site was too commonly perfectly confounded with NOAC). Therefore, pairwise models were constructed to identify patient-related factors associated with selection of a specific NOAC versus warfarin. Lastly, the same methodology was used to identify factors associated with one NOAC over another, where sufficient patients were available in individual drug groups. All subjects provided written, informed consent, and each site received institutional review board approval for this study, pursuant to local regulations. The ORBIT-AF II registry is sponsored by Janssen Scientific Affairs, LLC, (Raritan, NJ) and approved by the Duke University institutional review board. Analyses of the aggregate data were performed by the Duke Clinical Research Institute using SAS software (version 9.4; SAS Institute, Cary, NC). The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper, and its final contents.
Sensitivity analyses
To assess the impact of potential local site preferences, distribution of OAC agent use across sites was measured. The above multivariable analysis of NOAC versus warfarin was repeated, excluding any site that used the same OAC drug for 90% or more of their subjects (a total of 93 sites, 347 subjects excluded).
Results
The overall ORBIT-AF II population included 11,603 patients from 242 sites enrolled from February, 2013, to January, 2016. A total of 6,933 patients were excluded because of preexisting AF (n = 5,963), not being on any OAC at baseline (n = 934), or use of an OAC agent used in b5% of patients (edoxaban) at baseline (n = 36). This yielded an analysis population of 4,670 patients receiving OAC at baseline. Of these, 1,169 (25%) were initially started on warfarin, 259 on dabigatran (5.5%), 1,858 (40%) on rivaroxaban, and 1,384 (30%) on apixaban.
Baseline characteristics of these groups are shown in Table I . Patients receiving treatment with NOACs were significantly younger than those receiving warfarin (P b .01), were less likely to have CHA 2 DS 2 -VASc score ≥2 (P b .01), were less likely to be treated with concomitant aspirin (P b .01), had higher mean eGFR Use of NOAC versus warfarin in selected subgroups of patients with new-onset AF. *P b .05, **P b .0001. GIB, gastrointestinal bleeding; PCP, primary care physician; EP, electrophysiology.
(P b .01), and were more likely to receive care from an electrophysiologist (P b .01).
Selection of NOAC versus warfarin in patients with new-onset AF, stratified by subgroups of interest, is shown in Figure 1 . Across groups of age, prior stroke, prior bleeding, CHA 2 DS 2 -VASc, and eGFR, patients with lower risk were more likely to be treated with NOAC, whereas those in the higher-risk subgroup were relatively more likely to receive warfarin. There were significant differences in use of NOAC versus warfarin across provider specialty and US geographical location (P b .01 for each).
Results of hierarchical, logistical regression to identify factors associated with NOAC use versus warfarin use are shown in Table II . After adjustment, factors associated with selection of NOAC versus warfarin included educational status, renal function, stroke and bleeding risk, and AF treatment strategy. There was also strong variation among sites with respect to the selection of a NOAC (median OR for site 3.11, Figure 2 ).
In analysis of individual NOAC selection, logistical regression models were created for rivaroxaban versus warfarin and apixaban versus warfarin, as well as rivaroxaban versus apixaban; too few patients per site were available to accurately model dabigatran. In each of these models, factors associated with selection of the individual NOAC (rivaroxaban or apixaban) over warfarin were very similar and included the following: level of education; eGFR; hematocrit; physician specialty; and absence of dialysis, prior stroke/TIA, heart failure, or prior valve replacement (Table III ). In a model of rivaroxaban versus apixaban (Table IV) , apixaban selection appeared associated with older age, anemia, and underlying conduction disease (by electrocardiogram features). However, site itself remained an important influence on treatment selection in these models (OR 3.01 for rivaroxaban vs warfarin; OR 3.75 for apixaban vs warfarin; OR 2.43 for rivaroxaban vs apixaban).
Sensitivity analyses
In multivariate models excluding sites that used the same medication type (NOAC vs warfarin) for 90+% of their patients (n = 93 sites excluded), factors associated with NOAC use were similar to those identified by the primary analysis. These included level of education (P b .0001), renal function (P = .0048), prior stroke/TIA (P = .01), and AF treatment strategy (P = .01, Supplemental Material, Supplementary Table II) .
Discussion
Appropriate selection of stroke prevention therapy in patients with AF is vital to improving outcomes in this population; the time of diagnosis represents a pivotal opportunity to meet this objective. Our analysis yields several important findings about OAC selection in these patients. First, NOACs have now become the primary anticoagulation strategy for a majority of patients with new-onset AF. Second, patients selected to receive a NOAC were at lower risk for stroke and bleeding compared with those treated with warfarin. Lastly, there appear to be socioeconomic and operational factors driving NOAC selection, such as their use in more educated patients and in patients treated by AF CHF, Congestive heart failure; NYHA, New York Heart Association.
specialists, and provider-specific considerations. These appear to be consistent among specific NOACs compared with warfarin. Our study did demonstrate that there remained a significant proportion of patients with new-onset AF who are initially treated with warfarin. This could be due to several factors. Some patients have known contraindications to NOACs including those with rheumatic valvular disease, severe renal impairment, or the presence of a mechanical valve. Second, during our study period, there were no approved, targeted NOAC reversal agents for patients with bleeding in the setting of a NOAC. This may have tempered enthusiasm among some patients or physicians. Indeed, we did find some tendency for patients with higher risk for bleeding to be treated with warfarin rather than a NOAC.
Familiarity with prescribing NOACs may still be a challenge. Our data demonstrate that cardiologist and electrophysiology subspecialists were significantly more likely than primary care physicians to prescribe a NOAC. Lastly, cost is often the limiting factor in treatment selection for patients. We also found that socioeconomic status (measured by education level) did appear to be related to the utilization of NOAC drugs as well.
Once the decision was made to select a NOAC, our pairwise models of rivaroxaban versus warfarin and apixaban versus warfarin demonstrated that nearly identical factors influenced care decisions. That is, similar factors were associated with selection of rivaroxaban over warfarin compared with apixaban over warfarin, and there appeared to be significant variability by site. When we limited the models to only rivaroxaban versus apixaban, fewer factors were significantly associated with selection of one NOAC over another, and they appeared driven primarily by age; anemia; renal function; underlying conduction disease; and, to a large extent, site.
Together, these data demonstrate that site variability is a major driver of anticoagulation selection for patients newly diagnosed with AF, including selection of NOACs over warfarin and selection of one NOAC over another. The influence of site on selection of NOAC over warfarin may be related to local familiarity with these agents, similar to the influence of physician specialty-whereas some specialists will have more comfort with newer drugs, some sites within specialty may have more exposure, experience, and familiarity with specific agents. When selecting among NOACs, in the absence of robust head-to-head data, it is not surprising that local site factors come into play. Although there are differences among these agents and in relation to specific subgroups, the guidelines do not specifically discriminate among them. Physicians tend to select those with which they are most comfortable and knowledgeable.
These results highlight the complex, nonmedical decision-making processes around anticoagulation therapy for patients with new-onset AF. To realize the potential improvement in clinical outcomes with such treatment advances as NOACs, these data suggest further that implementation strategies, including improved access, patient selection, and patient and/or provider education, may be necessary.
Limitations
Site and/or patient sampling may limit the external validity of these data, as well as payer influences that are not captured. We cannot exclude the possibility of unmeasured confounding, particularly site-specific factors, in the multivariable results. In addition, this analysis represents a single snapshot during a period of likely dynamic prescribing patterns that may change and/or stabilize over time. This is particularly important given current cost considerations with newer medications; as they become more affordable and as patients and physicians become more comfortable with them, agent selection is likely to evolve. Other national and international analyses have identified growth in the uptake of NOACs.
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Conclusions
In contemporary clinical practice, NOACs account for nearly three-fourths of all oral anticoagulation for stroke prevention in patients with a new-diagnosis of AF. We also found that use was still preferentially tilted toward those who were younger and lower-risk patients. This may shift over time as studies demonstrate relative efficacy and safety in both low-and high-risk groups and with the development of targeted NOAC reversal agents. Finally, although several patient factors are associated with NOAC use, physician preference and patient education levels appear to be prime drivers of treatment decisions. Improved understanding of factors that influence OAC selection will be important as initiatives seek to improve stroke prevention and AF outcomes across several levels of care, including providers, clinics, and at the health care system level.
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